Sign in
WithdrawnNo phase

Mucopolysaccharidosis Type II Observational

Key facts

Who runs it
REGENXBIO Inc.
Where
Oakland and Philadelphia, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Status
Withdrawn
Started
Mar 2022
Ended
Jul 2025
Type of study
Observational
Treatments tested
  • Observational
Record updated
10 October 2022
Why it stopped
Sponsor decision

Who can take part

Age
1 month to 8 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Meets any of the following criteria:; Has a clinical diagnosis of severe MPS II and has a documented mutation in IDS, OR; Has a relative clinically diagnosed with severe MPS II who has the same IDS mutation as the subject, OR; Has documented mutation(s) in IDS that in the opinion of the investigator is known to result in a neuronopathic phenotype
  • Has sufficient communication capacity to complete the required protocol testing; Patient's legal guardian must be willing and able to provide written, signed informed consent

Who cannot take part

  • Has had prior treatment with an AAV-based gene therapy product
  • Is currently participating in a clinical trial of an investigational product for the treatment of MPS II with the exception of IT ELAPRASE trials; no investigational product may be taken starting 30 days or 5 half-lives of the investigational product prior to signing the ICF, whichever is longer

Where in United States

Also in 1 other country, 1 site

  • University of California San Francisco, Benioff Children's HospitalOakland, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States

About the trial

What the trial wants to find out

This is an observational study planned to document prospectively disease manifestation and neurocognitive course in pediatric patients with a clinical presentation consistent with neuronopathic ("severe") MPS II undergoing current standard of care and/or intrathecal Elaprase® for their condition. Some patients may be offered the opportunity to screen for a gene therapy study conducted by the same sponsor.

The group in the trial

  • Observational

    No Intervention

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)
Record updated
10 October 2022